Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Shaoshui Chen"'
Autor:
Guo Chen MD, Jinliang Wan MM, Zhenbo Wang MM, Lei Li MM, Hongying Jia MM, Shaozhi Xing MM, Shaoshui Chen MM, Xiaocheng Fan MM, Rui Li MD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 19 (2020)
Background: Gastric cancer is one of the most common malignancies worldwide with high mortality. Therefore, identifying cancer-related biomarkers for predicting prognosis and progression of gastric cancer is essential. This study aimed to investigate
Externí odkaz:
https://doaj.org/article/fcddf7f75aa047a4bfd4250ffcd07421
Autor:
Yanzhang Hao, Jianwei Liu, Ping Wang, Feng Wang, Zeshun Yu, Mianli Li, Shaoshui Chen, Fangling Ning
Publikováno v:
International Journal of Genomics, Vol 2014 (2014)
Background. Osteopontin (OPN) is associated with prognosis of patients with non-small-cell lung cancer (NSCLC). However, little is known about the association between OPN gene polymorphism and the chemotherapy response in NSCLC patients. Methods. A t
Externí odkaz:
https://doaj.org/article/35cb9799c79d46b4963d213c5d9a0407
Autor:
Shun Lu, Xiaorong Dong, Hong Jian, Jianhua Chen, Gongyan Chen, Yuping Sun, Yinghua Ji, Ziping Wang, Jianhua Shi, Junguo Lu, Shaoshui Chen, Dongqing Lv, Guojun Zhang, Chunling Liu, Juan Li, Xinmin Yu, Zhong Lin, Zhuang Yu, Zhehai Wang, Jiuwei Cui, Xingxiang Xu, Jian Fang, Jifeng Feng, Zhi Xu, Rui Ma, Jie Hu, Nong Yang, Xiangdong Zhou, Xiaohong Wu, Chengping Hu, Zhihong Zhang, You Lu, Yanping Hu, Liyan Jiang, Qiming Wang, Renhua Guo, Jianying Zhou, Baolan Li, Chunhong Hu, Wancheng Tong, Helong Zhang, Lin Ma, Yuan Chen, Zhijun Jie, Yu Yao, Longzhen Zhang, Weng Jie, Weidong Li, Jianping Xiong, Xianwei Ye, Jianchun Duan, Haihua Yang, Meili Sun, Changan Sun, Hongying Wei, Chuan Li, Siraj M. Ali, Vincent A. Miller, Qiong Wu
Publikováno v:
Journal of Clinical Oncology. 40:3162-3171
PURPOSE Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind phase III trial evaluated the efficacy and safety of aumolertinib compa
Autor:
Yuankai Shi, Qingyuan Zhang, Xiaonan Hong, Zhen Wang, Yuhuan Gao, Liqun Zou, Hong Cen, Lin Gui, Yufu Li, Jifeng Feng, Zhao Wang, Mingzhi Zhang, Chuan Jin, Weihua Zhang, Jianda Hu, Chengyun Zheng, Zhendong Zheng, Liling Zhang, Shaoshui Chen, Yunhong Huang, Yun Tang, Yajie Gao, Miaowang Hao, Xiaoling Li, Chunkang Chang, Haiyan Yang, Hui Wu, Lida Shen, Xiaoyan Ke, Liangming Zhang, Yaming Xi, Linhua Yang, Liangzhi Xie, Wenlin Gai, Yanan Ji
Publikováno v:
Hematological Oncology. 40:930-940
Autor:
Sai-Hong Ignatius Ou, Xingxiang Xu, Yuan Chen, Chuan Li, Ying Cheng, Ziping Wang, Changan Sun, Kai Wang, Jianhua Chen, Qiong Wu, Zhehai Wang, R. Guo, Te Chun Hsia, Zhuang Yu, Jian Fang, Shaoshui Chen, Haihua Yang, Yong Song, Chin-Chou Wang, Xiaorong Dong, Jianxing He, Her-Shyong Shiah, Ping Wang, Cheng-Ta Yang, Hongying Wei, Yuping Sun, Viola W. Zhu, Jianhua Shi, Guojun Zhang, Wu Chou Su, Jifeng Feng, Jianying Zhou, Jiuwei Cui, Nong Yang, Shun Lu, Yanping Hu, Qiming Wang, Hongming Pan, Chao-Hua Chiu, Gee-Chen Chang, You Lu, James Chih-Hsin Yang
Publikováno v:
Journal of Thoracic Oncology. 17:411-422
Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation EGFR tyrosine kinase inhibitor (TKI) with revealed activity against EGFR-sensitizing mutations and EGFR T790M mutation.Patients with locally advanced or metastatic NSCLC who d
Autor:
Mianli Li, Feng Wang, Chen Yinghai, Chunjuan Du, Baosheng Li, Han Xia, Chang-Min Liu, Juan Wang, Shaoshui Chen, Xiaofei Zhong
Publikováno v:
Cancer Biomarkers. 25:325-332
Background Lung cancer is the main cancer-related deaths worldwide. In this study, we explored the clinical prognostic significance and functional role of miR-939-3p in lung cancer. Methods We analyzed the expression of miR-939-3p in lung cancer tiss
Autor:
Shun Lu, Xiaorong Dong, Hong Jian, Jianhua Chen, Gongyan Chen, Yuping Sun, Yinghua Ji, Ziping Wang, Jianhua Shi, JunGuo Lu, Shaoshui Chen, Dongqing Lv, Guojun Zhang, Chunling Liu, Juan Li, Xinmin Yu, Zhong Lin, Zhuang Yu, Zhehai Wang, Jiuwei Cui
Publikováno v:
Journal of Clinical Oncology. 40:9096-9096
9096 Background: We previously reported (Lu, ASCO 2021, abstract # 9013) that treatment with aumolertinib (Au), a 3rd generation EGFR TKI, led to robust improvement in progression free survival (PFS) (median PFS 19.3 to 9.9 months, HR = 0.46, p < 0.0
Publikováno v:
Proceedings of Anticancer Research. 4
Malignant tumors are one of the serious public health problems that threaten the survival time of human beings. They are prone to metastasis to distant organs and the central nervous system is one of the common target organs. As it is difficult for c
Autor:
Xiao-Han Gao, Qing-Shuai Fan, Jing Zheng, Long-Bo Ma, Yu-Jie Zhai, Shaoshui Chen, Heng-Lu Wang, Chang-Min Liu, Xiao-Han Wu, Sheng-Jie Wang, Long Ma, Jie Wen, Fang-Fang Yang
Publikováno v:
Annals of palliative medicine. 10(1)
Background With the development of radiological technologies, radiotherapy has been gradually widely used in the clinic to intracranial tumours and become standardised. However, the related central nervous system disorders are still the most obvious
Autor:
Fang-Ling Ning, Shuanghu Yuan, Roger Sun, Changmin Liu, Zhenbo Wang, Judong Luo, Jing Wang, Shaoshui Chen
Publikováno v:
BioMed Research International, Vol 2020 (2020)
BioMed Research International
BioMed Research International
Background. Concurrent chemoradiotherapy (CCRT) is the main treatment for esophageal cancer, but the response to treatment varies from individual to individual. MR imaging methods, such as diffusion-weighted (DW) MRI and the use of dynamic contrast-e